JP2005516908A5 - - Google Patents

Download PDF

Info

Publication number
JP2005516908A5
JP2005516908A5 JP2003549295A JP2003549295A JP2005516908A5 JP 2005516908 A5 JP2005516908 A5 JP 2005516908A5 JP 2003549295 A JP2003549295 A JP 2003549295A JP 2003549295 A JP2003549295 A JP 2003549295A JP 2005516908 A5 JP2005516908 A5 JP 2005516908A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
hydrogen
hydroxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003549295A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005516908A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/038506 external-priority patent/WO2003048101A1/en
Publication of JP2005516908A publication Critical patent/JP2005516908A/ja
Publication of JP2005516908A5 publication Critical patent/JP2005516908A5/ja
Pending legal-status Critical Current

Links

JP2003549295A 2001-11-30 2002-12-02 癌細胞におけるアポトーシスの誘導 Pending JP2005516908A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33408101P 2001-11-30 2001-11-30
US40625202P 2002-08-26 2002-08-26
PCT/US2002/038506 WO2003048101A1 (en) 2001-11-30 2002-12-02 Induction of apoptosis in cancer cells

Publications (2)

Publication Number Publication Date
JP2005516908A JP2005516908A (ja) 2005-06-09
JP2005516908A5 true JP2005516908A5 (enExample) 2006-01-26

Family

ID=26989041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003549295A Pending JP2005516908A (ja) 2001-11-30 2002-12-02 癌細胞におけるアポトーシスの誘導

Country Status (7)

Country Link
US (2) US7053071B2 (enExample)
EP (1) EP1456165A1 (enExample)
JP (1) JP2005516908A (enExample)
CN (1) CN100348569C (enExample)
AU (1) AU2002346620A1 (enExample)
CA (1) CA2468745A1 (enExample)
WO (1) WO2003048101A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2333337T3 (es) 2000-08-29 2010-02-19 Biocon Limited Uso de una composicion farmaceutica que contiene un derivado de acido para-aminofenilacetico para tratar afecciones inflamatorias del tracto gastrointestinal.
ITRM20010464A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.
US8048924B2 (en) * 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US7504401B2 (en) * 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
US7632972B2 (en) * 2003-10-30 2009-12-15 The Board Of Trustees Of The University Of Illionis Compounds and methods for treatment of cancer and modulation of programmed cell death for melanoma and other cancer cells
DK1773767T3 (en) * 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EA200700243A1 (ru) 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения гепатита с
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1781289A1 (en) 2004-07-22 2007-05-09 PTC Therapeutics, Inc. Thienopyridines for treating hepatitis c
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2008134474A2 (en) 2007-04-27 2008-11-06 The Board Of Trustees Of The University Of Illinois Compositions and methods including cell death inducers and procaspase activation
CN101489380A (zh) 2006-05-19 2009-07-22 伊利诺伊大学评议会 用于治疗黑素瘤和其他癌症的含三苯基甲基膦酸酯的含磷化合物
US20080280891A1 (en) * 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
LV13735B (en) 2006-12-28 2008-09-20 Vjaceslavs Tribulovics Method for manufacturing substituted adamantylarylmagnesium chalogenides
DK2134685T3 (en) * 2007-04-16 2015-12-07 Abbvie Inc 7-unsubstituted indole derivatives as MCL-1 inhibitors
US20100130598A1 (en) * 2008-10-22 2010-05-27 Novogen Research Pty Ltd. Methods for inducing programmed cell death
WO2010091382A1 (en) 2009-02-09 2010-08-12 The Board Of Trustees Of The University Of Illinois Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs
US9096544B2 (en) 2009-12-23 2015-08-04 Wayne State University Therapeutic compounds
US10820597B2 (en) 2011-03-18 2020-11-03 Biofungitek, S.L. Phytosanitary composition comprising essential oils that potentiate antifungal activity
ES2361432B9 (es) 2011-03-18 2012-04-24 Biofungitek, Sociedad Limitada Composición fitosanitaria que comprende aceites esenciales potenciadores de la actividad antifúngica.
EP2817292B1 (en) * 2012-02-22 2019-12-18 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as tnap inhibitors
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
EP3301085A1 (en) 2016-09-29 2018-04-04 Biogem S.Ca.R.L. Retinoid derivatives with antitumor activity
CN116350622A (zh) * 2023-04-04 2023-06-30 广西中医药大学 Pycnidione在制备抗前列腺癌药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680299A (en) * 1984-04-30 1987-07-14 E.I. Du Pont De Nemours And Company 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof
FR2676052B1 (fr) * 1991-05-02 1994-04-29 Cird Galderma Nouveaux composes polycycliques aromatiques et leur utilisation en medecine humaine ou veterinaire et en cosmetique.
GB9604926D0 (en) * 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
JP3537065B2 (ja) * 1996-07-01 2004-06-14 キヤノン株式会社 電子写真感光体、プロセスカートリッジ及び電子写真装置
CZ3499A3 (cs) * 1996-07-08 1999-11-17 Galderma Research & Development, S. N. C. Adamantylová sloučenina, její použití a farmaceutický prostředek ji obsahující
US6462064B1 (en) 1996-07-08 2002-10-08 Galderma Research & Development S.N.C. Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias
CA2281523A1 (en) * 1997-02-25 1998-08-27 Braham Shroot Identification of a unique receptor specific for a particular retinoid inducing cellular apoptosis
FR2776657B1 (fr) * 1998-03-31 2000-05-26 Cird Galderma Composes bicycliques-aromatiques et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetologie
US6515003B1 (en) 1999-08-31 2003-02-04 Maxia Pharmaceuticals, Inc. Heterocyclic derivatives for the treatment of diabetes and other diseases
GB9927056D0 (en) * 1999-11-17 2000-01-12 Karobio Ab Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
FR2804323B1 (fr) * 2000-01-31 2006-07-07 Galderma Res & Dev Utilisation de composes de type retinoides en tant qu'agents anti-bacteriens
EP1278734A2 (en) * 2000-04-24 2003-01-29 Merck Frosst Canada & Co. Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
PL373912A1 (en) 2001-03-07 2005-09-19 Incyte San Diego, Inc. Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
ITRM20010464A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.

Similar Documents

Publication Publication Date Title
JP2005516908A5 (enExample)
JP2010530881A5 (enExample)
RU2404189C9 (ru) Новые пептиды как ингибиторы ns3-серинпротеазы вируса гепатита c
JP2002543185A5 (enExample)
RU2001132635A (ru) Производные пиперидина, применимые в качестве антагонистов сс R5
JP2008531479A5 (enExample)
JP2002512989A5 (enExample)
HU226199B1 (en) Perfluoroalkyl-containing metal complexes, process for their preparation and their use in nmr diagnostics
JP2005504042A5 (enExample)
RU2003101319A (ru) Фармацевтическая композиция, обладающая улучшенным противоопухолевым действием и/или сниженными побочными эффектами, содержащая противоопухолевый агент и производное гидроксамовой кислоты
JP2008512408A5 (enExample)
CN111836814A (zh) 稠环化合物、其制备方法及用途
JP2004516314A5 (enExample)
JP2006528700A5 (enExample)
JP2006182786A5 (enExample)
RU2002100125A (ru) Комплексы металлов с бициклическими полиаминокислотами, способ их получения и их применение в медицине для получения изображения
EP0731797A1 (en) Paramagnetic chelates for nuclear magnetic resonance diagnosis
JP2003508534A5 (enExample)
JP2005526138A5 (enExample)
JP2011513471A5 (enExample)
JPH05500969A (ja) テトラ―アザ大環状化合物、それらの調製法およびそれらの磁気共鳴画像形成での使用
AR052439A1 (es) Medicamentos para el tratamiento o la prevencion de enfermedades fibroticas
JP2002538117A5 (enExample)
RU2006131043A (ru) Соединения силинана в качестве ингибиторов цистеиновой протеазы
JPH10502083A (ja) 医療診断用の画像形成のためのx線造影剤として有用な2,4,6−トリヨード−5−置換アミノ−イソフタル酸エステル